1. Increased expression of CD154 (CD40L) on stimulated T-cells from patients with psoriatic arthritis.
- Author
-
Daoussis D, Antonopoulos I, Andonopoulos AP, and Liossis SN
- Subjects
- Adult, Aged, Arthritis, Rheumatoid immunology, CD40 Ligand biosynthesis, CD8-Positive T-Lymphocytes immunology, Cells, Cultured, Cyclosporine pharmacology, Female, Humans, Immunosuppressive Agents pharmacology, Male, Middle Aged, T-Lymphocytes drug effects, Arthritis, Psoriatic immunology, CD40 Ligand blood, Lymphocyte Activation immunology, T-Lymphocytes immunology
- Abstract
Objectives: CD40L is a costimulatory molecule and an early activation marker of T-lymphocytes. Based on the hypothesis that activated T-cells may play a role in the pathogenesis of psoriatic arthritis (PsA), we evaluated the level of CD40L expression on T-cells from patients with PsA., Methods: We analysed 12 patients with PsA, six patients with rheumatoid arthritis (RA) and four healthy volunteers. T-cell surface expression of CD40L was evaluated using two-colour flow cytometry in (i) the resting state and (ii) following stimulation with phorbol myristate acetate/ionomycin, with or without ciclosporin (CsA)-mediated inhibition., Results: Expression of CD40L was significantly increased on activated T-cells from patients with PsA, particularly those with active disease, when compared with normal individuals and patients with RA (mean percentages of CD3+ CD40L+ cells: 23.74, 11.59 and 9.57% for patients with active PsA, patients with RA and healthy volunteers, respectively). CsA-mediated inhibition of CD40L induction was equally effective in all study groups., Conclusion: CD40L is overexpressed on T-cells from patients with active PsA. This may indicate a role for CD40L in PsA pathogenesis. Larger-scale studies are warranted to address these issues.
- Published
- 2007
- Full Text
- View/download PDF